Clinicopathologic comparisons between estrogen receptor-positive and -negative gastric cancers
✍ Scribed by Chew-Wun Wu; Shyh-Haw Tsay; Tai-Jay Chang; Hway-May Chang; Mao-Chih Hsieh; Wing-Yiu Lui; Fang-Ku P'Eng; Chin-Wen Chi
- Book ID
- 102439743
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 495 KB
- Volume
- 51
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
We report that a modified dextran-coated charcoal (DCC) assay, including the addition of sodium molybdate and 5% DCC stripping of endogenous hormone, detected higher estrogen receptors (ERs) than those by the conventional assay. ERs in 21 gastric adenocarcinoma were determined by the modified DCC assay; 13 patients had ERs of 2.5 to 520.2 fmol/mg protein with a mean dissociation constant of 1.9 X loP"' M. The remaining 8 patients had no detectable amount of the receptor. There were no differences between the ER-positive and ER-negative groups in clinico-pathologic characteristics such as age, sex, tumor size, location, gross appearance, invasive depth, invasion of lymph vessel or vein of stomach wall, nodal involvement, peritoneal dissemination, liver metastasis, and curability. Histological analysis, using Japanese, Lauren's, or Ming's classifications, all revealed no differences between the ER-positive and -negative groups. The survival rate was identical for the 2 study groups. These results suggest that the presence or absence of ERs in gastric adenocarcinoma does not correlate to either biologic or clinicopathologic characteristics of this tumor; the role of ERs in human gastric cancer remains to be elucidated.
📜 SIMILAR VOLUMES
## Abstract Estrogen receptor (ER)‐positive breast cancer cells have low levels of constitutive NF‐κB activity while ER negative (−) cells and hormone‐independent cells have relatively high constitutive levels of NF‐κB activity. In this study, we have examined the aspects of mutual repression betwe
## Abstract We show that flavonoids positively regulate type‐II estrogen‐binding site (type‐ll EBS) levels both in MCF‐7 (ER‐positive) and in MDA‐MB231 (ER‐negative) breast‐cancer cells. Type‐ll EBS were measured by a whole‐cell assay at 4°C for 2.5 hr using [^3^H]‐estradiol as tracer. In both cell